Lesauteursdéclarentnepasavoirdeliensd’intérêts.
Références
[1]Agence de la biomédecine. Rapport annuel médical et scientifique; 2015 http://www.agence-biomedecine.fr/
Site-des-professionnels.
[2]A definition of irreversible coma. Report of the Ad Hoc Committee ofthe Harvard Medical Schoolto Examine the DefinitionofBrainDeath.JAMA1968;205:337—40.
[3]RosenbergRN.Consciousness,coma,andbraindeath—2009.
JAMA2009;301:1172—4.
[4]Wijdicks EF. The diagnosis of brain death. N Engl J Med 2001;344:1215—21.
[5]Caillavet.Loino76-1181du22décembre1976relativeaux prélèvementsd’organes;1976.
[6]BenoitG, BitkerMO.Aspectschirurgicauxdel’insuffisance rénalechroniqueettransplantation.Chapitre4:ledonneur.
ProgUrol1996;6:713—52.
[7]Loi no 94-654 du 29 juillet 1994 relative au don et à l’utilisation des éléments et produits du corps humain, à l’assistancemédicaleàlaprocréationetaudiagnostic préna-tal;1994.
[8]Loino2004-800du6août2004relativeàlabioéthique(1);
2004.
[9]Loino2011-814du7juillet2011relativeàlabioéthique2011.
n.d.
[10] Agence de la biomédecine. Rapport annuel médical et scientifique 2014. Agence de la biomédecine; 2014. p.
2 [http://www.agence-biomedecine.fr/annexes/bilan2014/
donnees/organes/06-rein/synthese.htm].
[11] KaramG,KälbleT,AlcarazA,AkiF,BuddeK,HumkeU,etal.
GuidelinesonrenaltransplantationoftheEuropean Associa-tionofUrology(EAU);2014http://uroweb.org/wp-content/
uploads/27-Renal-TransplantLRV2-May-13th-2014.pdf.
[12] Arrêtédu2juillet1998relatifàladatedemiseenservicedu registrenationalautomatisédesrefussurpersonnedécédée d’organes,detissusetdecellules;1998.
[13] Arrêté du 2 décembre 1996 pris en applicationdu décret 96-1041du2 décembre1996relatifauconstat delamort préalableauprélèvementd’organesdetissusetdecellulesà desfinsthérapeutiquesouscientifique1996.
[14] CirculaireD.G.Sno96-733du04décembre1996relativeau constatdelamortpréalableauprélèvementd’organes,de tissusetdecellulesàdesfinsthérapeutiquesouscientifiques définiparledécretno96-1041du2décembre1996;1996.
[15] Arrêtédu 27février 1998portanthomologationdes règles debonnes pratiquesrelatives au prélèvementd’organes à finalitéthérapeutiquesurpersonnedécédée;1998.
[16] Agence de la biomédecine. Rapport annuel médical et scientifique2014.Agencedelabiomédecine;2014.p.1—15
[http://www.agence-biomedecine.fr/annexes/bilan2014/
donnees/organes/06-rein/synthese.htm].
[17]Codedesantépublique,LivreIIIChapitre2.
[18]AlechinskyL,MalaquinG, HuotO,BarrouB.Reinsprélevés nongreffés:unesourcedegreffonsnonexploitée?ProgUrol 2014;24:853.
[19]Agence de la biomédecine. Le rapport médical et scien-tifique 2014. Agence de la biomédecine; 2014. p. 21—2 [http://www.agence-biomedecine.fr/annexes/bilan2014/
donnees/organes/06-rein/synthese.htm].
[20]Fregeville A, De Bazelaire C, Zagdanski A, Albiter M, Desgrandchamps F, De Kerviler E. [Value of whole-body CTA in the management of brain-dead patients]. J Radiol 2010;91:37—44.
[21]BerthierE,Ridereau-Zins C,DubéL, TchouanteP,Nedelcu C,LasockiS,etal.SimultaneousCTangiographyand whole-bodyCTisaneffectiveimagingapproachbeforemultiorgan retrieval.DiagnIntervImaging2016;16:30151—6.
[22]Tache A, Badet N, Azizi A, Behr J, Verdy S, Delabrousse E. Multiphase whole-body CT angiography before multior-gan retrieval in clinically brain-dead patients: role and influenceonclinicalpractice.DiagnIntervImaging2016;97:
657—65.
[23]LeclercX,Groupederelecture.[CTangiographyforthe diag-nosisofbraindeath:recommendationsoftheFrenchSociety ofNeuroradiology(SFNR)].JNeuroradiol2007;34:217—9.
[24]Dupas B, Gayet-Delacroix M, Vecchierini MF, et al. Le scannerhélicoïdal:uneméthodeangiographiquepourle dia-gnosticdemortencéphalique.Eval.Neuropsychiatr. Comas Mort Enceph. États neurovegetatifs. Paris: Solal; 2001.
p.315—20.
[25]Nijkamp DM, SlooffMJH, vander HilstCS, Ijtsma AJC, de JongKP,PeetersPMJG,etal.Surgicalinjuriesofpostmortem donorlivers:incidence andimpactonoutcome afteradult livertransplantation.LiverTransplant2006;12:1365—70.
[26]Gruttadauria S, Foglieni CS, Doria C, Luca A, Lauro A, Marino IR.The hepatic artery in liver transplantation and surgery: vascular anomalies in 701 cases. Clin Transplant 2001;15:359—63.
[27]SmithM.Physiologicchangesduringbrainstemdeath— les-sons for management of the organ donor. J Heart Lung Transplant2004;23:S217—22.
[28]Bugge JF. Brain death and its implications for manage-mentofthepotentialorgandonor.ActaAnaesthesiolScand 2009;53:1239—50.
[29]NovitzkyD,Rhodin J,CooperDK,YeY,MinKW,DeBaultL.
Ultrastructure changes associated withbrain deathin the humandonorheart.TransplInt1997;10:24—32.
[30]DujardinKS,McCully RB,WijdicksEF,TazelaarHD,Seward JB,McGregor CG,etal. Myocardialdysfunctionassociated withbraindeath:clinical,echocardiographic,andpathologic features.JHeartLungTransplant2001;20:350—7.
[31]VenkateswaranRV,TownendJN,WilsonIC,MascaroJG,Bonser RS,SteedsRP.Echocardiographyinthepotentialheartdonor.
Transplantation2010;89:894—901.
[32]RiouB.Donneurenmortencéphalique:réanimationdu don-neur. La transplantation rénale. Paris: Lavoisier; 2012. p.
197—211.
[33]McKeown DW, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. Br J Anaesth 2012;108(Suppl.1):i96—107.
[34]FronteraJA,KalbT.HowImanagetheadultpotentialorgan donor:donationafterneurologicaldeath(part1).Neurocrit Care2010;12:103—10.
[35]Cittanova ML,Leblanc I,Legendre C,Mouquet C, Riou B, CoriatP.Effectofhydroxyethylstarch inbrain-deadkidney donorsonrenalfunctioninkidneytransplantrecipients. Lan-cet1996;348:1620—2.
[36]CoronelB,LaurentV,MercatelloA,BretM,ColonS,Colpart JJ, et al. [Can hydroxyethylamidon be usedduring inten-sivecareofbrain-deadorgandonors?].AnnFrAnesthReanim 1994;13:10—6.
[37]Patel MS, Niemann CU, Sally MB, De La Cruz S, Zatarain J, Ewing T, et al. The impact of hydroxyethyl starch use in deceased organ donorson the developmentof delayed graftfunctioninkidneytransplantrecipients:a propensity-adjustedanalysis.AmJTransplant2015;15:2152—8.
[38]GiralM,BertolaJP,FoucherY,VillersD,BironneauE,Blanloeil Y,etal.Effectofbrain-deaddonorresuscitationondelayed graftfunction:resultsofamonocentricanalysis. Transplan-tation2007;83:1174—81.
[39]Hokema F, Ziganshyna S, Bartels M, Pietsch U-C, Busch T, Jonas S, et al. Is perioperative low molecular weight hydroxyethyl starchinfusionariskfactorfor delayedgraft function inrenal transplantrecipients?NephrolDial Trans-plant2011;26:3373—8.
[40]RiouB,GuesdeR,JacquensY,DuranteauR,ViarsP.Fiberoptic bronchoscopyinbrain-deadorgandonors.AmJRespirCrit CareMed1994;150:558—60.
[41]StraznickaM,FolletteDM,EisnerMD,RobertsPF,MenzaRL, BabcockWD.Aggressivemanagementoflungdonors classi-fied asunacceptable: excellentrecipientsurvivalone year after transplantation. J Thorac Cardiovasc Surg 2002;124:
250—8.
[42]Guesde R, Barrou B, Leblanc I, Ourahma S, Goarin JP, Coriat P, et al. Administration of desmopressin in brain-deaddonorsandrenalfunctioninkidneyrecipients.Lancet 1998;352:1178—81.
[43]Nicolas-Robin A, Barouk JD, Amour J, Coriat P, Riou B, Langeron O. Hydrocortisone supplementation enhances hemodynamicstabilityinbrain-deadpatients.Anesthesiology 2010;112:1204—10.
[44]RiouB,KalfonP,ArockM,GoarinJP,SaadaM,ViarsP. Car-diovascular consequencesof severe hypophosphataemiain brain-deadpatients.BrJAnaesth1995;74:424—9.
[45]GoarinJP,CohenS,RiouB,JacquensY,GuesdeR,LeBretF, etal.Theeffectsoftriiodothyronineonhemodynamicstatus andcardiacfunctioninpotentialheartdonors.AnesthAnalg 1996;83:41—7.
[46]FulgenicoJP,RiouB,DevilliersC,GuesdeR,SaadaM,ViarsP.
Plasmaionizedcalciuminbrain-deadpatients.IntensiveCare Med1995;21:832—7.
[47]Barklin A,LarssonA, VestergaardC,KjaergaardA, Wogen-sen L, SchmitzO, et al. Insulinalterscytokine content in twopivotalorgansafterbraindeath:aporcinemodel.Acta AnaesthesiolScand2008;52:628—34.
[48]BoulardG, GuiotP,Pottecher T,TenaillonA. [Management ofsubjectsinastateofbraindeathandthepreservationof organs].AnnFrAnesthRea2005;24:836—43.
[49]TalvingP,BenfieldR,HadjizachariaP,InabaK,ChanLS, Deme-triades D. Coagulopathy in severe traumatic braininjury:
a prospective study. J Trauma 2009;66:55—61 [discussion 61—2].
[50]Niemann CU, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, et al. Therapeutic hypothermia in decea-sed organdonorsand kidney graft function.NEngl J Med 2015;373:405—14.
[51]Lamy F-X, Atinault A, Thuong M. [Organ procurement in France:newchallenges].PresseMed2013;42:295—308.
[52]CristalAction:unoutilqualitédel’Agencedela bioméde-cine pourlesétablissementsdesanté2010—http://www.
agence-biomedecine.fr/Cristal-Action.
[53]Ledonetlatransplantationd’organes,Eurobarometre333a.
2014.[Availablefrom:http://ec.europa.eu/publicopinion/
archives/ebspecialfr.htm].
[54]FreiU,NoeldekeJ,Machold-FabriziiV,ArbogastH,Margreiter R,FrickeL,etal.Prospectiveage-matchinginelderlykidney transplantrecipients—a5-yearanalysisoftheEurotransplant SeniorProgram.AmJTransplant2008;8:50—7.
[55]SchratzbergerG,MayerG.Ageandrenaltransplantation:an interimanalysis.NephrolDialTransplant2003;18:471—6.
[56]Pessione F, Cohen S, Durand D, Hourmant M, Kessler M, LegendreC,etal.Multivariateanalysisofdonorriskfactors forgraftsurvivalinkidneytransplantation.Transplantation 2003;75:361—7.
[57]MetzgerRA,DelmonicoFL,FengS,PortFK,WynnJJ,Merion RM.Expanded-criteriadonorsforkidneytransplantation.Am JTransplant2003;3(Suppl4):114—25.
[58]LegendreC.Latransplantationrénale.Paris:Lavoisier;2012.
[59]Nyberg SL, MatasAJ, Kremers WK, Thostenson JD, Larson TS,PrietoM,etal.Improvedscoringsystemtoassessadult donorsfor cadaver renal transplantation.Am JTransplant 2003;3:715—21.
[60]RemuzziG,CravediP,PernaA,DimitrovBD,TurturroM, Loca-telliG, et al. Long-termoutcome of renal transplantation fromolderdonors.NEnglJMed2006;354:343—52.
[61]Dahmane D, Audard V, Hiesse C, Pessione F,Bentaarit B, BarrouB, etal. Retrospectivefollow-up oftransplantation of kidneys from ‘‘marginal’’ donors. Kidney Int 2006;69:
546—52.
[62]RaoPS,SchaubelDE,GuidingerMK,AndreoniKA,WolfeRA, MerionRM,etal.Acomprehensiveriskquantificationscore for deceased-donor kidneys: the kidney donor risk index.
Transplantation2009;88:231—6.
[63]Israni AK, Salkowski N, Gustafson S, Snyder JJ, Frie-dewald JJ, Formica RN, et al. New national allocation policyfor deceased-donorkidneysintheUnitedStatesand possible effect on patient outcomes. J Am Soc Nephrol 2014;25:1842—8.
[64]GillJ, BunnapradistS, Danovitch GM,Gjertson D, GillJS, CeckaM.Outcomesofkidneytransplantationfromolderliving donorstoolderrecipients.AmJKidneyDis2008;52:541—52.
[65]MerionRM,AshbyVB,WolfeRA,DistantDA,Hulbert-Shearon TE, Metzger RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005;294:2726—33.
[66]CarrollRP,MacgregorL,WalkerRG.Theimprovementin sur-vivalofexpanded-criteriadonorkidneyswithtransplantation era.ClinTransplant2008;22:324—32.
[67]CollinsMG, ChangSH, RussGR, McDonaldSP. Outcomesof transplantationusingkidneysfromdonorsmeeting expanded-criteria in Australia and New Zealand, 1991 to 2005.
Transplantation2009;87:1201—9.
[68]Diet C,Audard V, Roudot-Thoraval F,Matignon M, Lang P, GrimbertP.Immunologicalriskinrecipientsofkidney trans-plantsfromextendedcriteriadonors.NephrolDialTransplant 2010;25:2745—53.
[69]SellersMT,VelidedeogluE,Bloom RD,GrossmanRA, Mark-mann JW, Naji A, et al. Expanded-criteria donor kidneys:
a single-center clinical and short-term financial analy-sis—causeforconcerninretransplantation.Transplantation 2004;78:1670—5.
[70]Hofer J, RegeleH, Böhmig GA,Gutjahr G, Kiki´c Z, Mühl-bacher F, et al. Pre-implant biopsy predicts outcome of single-kidneytransplantation independentofclinicaldonor variables.Transplantation2014;97:426—32.
[71]FraserSM,RajasundaramR,AldouriA,FaridS,Morris-StiffG, BakerR,etal.Acceptableoutcomeafterkidney transplanta-tionusing‘‘expanded-criteriadonor’’grafts.Transplantation 2010;89:88—96.
[72]SmailN,TchervenkovJ,ParaskevasS,BaranD,MucsiI, Hassa-nainM,etal.Impactofearlygraftfunctionon10-yeargraft
survivalinrecipientsofkidneysfromstandard-or expanded-criteriadonors.Transplantation2013;96:176—81.
[73] LimWH,ClaytonP,WongG,CampbellSB,CohneyS,RussGR, etal.Outcomesofkidneytransplantationfromolderliving donors.Transplantation2013;95:106—13.
[74] Kim SM, Ahn S, Min SI, Park D, Park T, Min SK, et al.
Cold ischemic time is critical in outcomes of expanded-criteriadonorrenaltransplantation.ClinTransplant2013;27:
132—9.
[75] AubertO,KamarN,VernereyD,VigliettiD,MartinezF, Duong-Van-HuyenJ-P,etal.Long-termoutcomesoftransplantation using kidneys from expanded-criteria donors: prospective, populationbasedcohortstudy.BMJ2015;35:35—57.
[76] QuerardA-H,FoucherY,CombescureC,DantanE,LarmetD, LorentM,etal.Comparison ofsurvivaloutcomesbetween Expanded-CriteriaDonorandStandard-CriteriaDonorkidney transplantrecipients:asystematicreviewandmeta-analysis.
TransplInt2016;29:403—15.
[77] SavoyeE,TamarelleD,ChalemY,RebibouJ-M,TuppinP. Survi-valbenefitsofkidneytransplantationwithexpanded-criteria deceased-donorsinpatientsaged 60yearsandover. Trans-plantation2007;84:1618—24.
[78] RaoPS,OjoA.Thealphabetsoupofkidneytransplantation:
SCD,DCD,ECD—fundamentalsforthepracticing nephrolo-gist.ClinJAmSocNephrol2009;4:1827—31.
[79] MolnarMZ,Streja E,KovesdyCP, ShahA,Huang E, Bunna-pradistS,etal.Ageandtheassociationsoflivingdonorand expanded-criteriadonorkidneyswithkidneytransplant out-comes.AmJKidneyDis2012;59:841—8.
[80] ScholdJD,Meier-KriescheH-U.Whichrenaltransplant can-didates shouldaccept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006;1:532—8.
[81] PascualJ,ZamoraJ,PirschJD.Asystematicreviewofkidney transplantationfromexpanded-criteriadonors.AmJKidney Dis2008;52:553—86.
[82] OjoAO,HansonJA,Meier-KriescheH,OkechukwuCN,Wolfe RA, Leichtman AB, et al. Survival in recipients of margi-nalcadavericdonorkidneyscomparedwithotherrecipients and wait-listed transplant candidates. J Am Soc Nephrol 2001;12:589—97.
[83] Ratner LE, Kraus E, Magnuson T, Bender JS. Transplan-tation of kidneys from expanded-criteria donors. Surgery 1996;119:372—7.
[84] Filiopoulos V, Boletis JN. Renal transplantation with expanded-criteriadonors:whichistheoptimal immunosup-pression?WorldJTransplant2016;6:103—14.
[85] Sung RS, Guidinger MK, Leichtman AB, Lake C, Metz-ger RA, Port FK, et al. Impact of the expanded-criteria donor allocation system on candidates for and reci-pientsof expanded-criteriadonor kidneys. Transplantation 2007;84:1138—44.
[86] AnglicheauD,LoupyA,LefaucheurC,PessioneF,Létourneau I,CôtéI,etal.Asimpleclinico-histopathologicalcomposite scoringsystemishighlypredictiveofgraftoutcomesin mar-ginaldonors.AmJTransplant2008;8:2325—34.
[87] PhilosopheB,MalatGE,SoundararajanS, BarthRN, Manit-pisikul W, Wilson NS, et al. Validation of the Maryland AggregatePathology Index(MAPI), a pre-implantation sco-ring system that predicts graft outcome. Clin Transplant 2014;28:897—905.
[88] AzancotMA, Moreso F,Salcedo M, Cantarell C, Perello M, TorresIB,etal.Thereproducibilityandpredictivevalueon outcomeofrenalbiopsiesfromexpanded-criteriadonors. Kid-neyInt2014;85:1161—8.
[89] Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preserva-tion Trial Study Group. Machineperfusion or coldstorage
in deceased-donor kidney transplantation. N Engl J Med 2012;366:770—1.
[90]Moers C,SmitsJM,MaathuisM-HJ,Treckmann J, van Gel-derF,NapieralskiBP,etal.Machineperfusionorcoldstorage in deceased-donor kidney transplantation. N Engl J Med 2009;360:7—19.
[91]Gallinat A, Moers C, Smits JM, Strelniece A, Pirenne J, PloegRJ,etal.Machineperfusionversusstaticcoldstorage in expanded-criteria donor kidney transplantation: 3-year follow-updata.TransplInt2013;26:E52—3.
[92]RemuzziG,GrinyòJ,RuggenentiP,BeatiniM,ColeEH,Milford EL,etal.Earlyexperiencewithdualkidneytransplantation inadultsusingexpandeddonorcriteria.DoubleKidney Trans-plantGroup(DKG).JAmSocNephrol1999;10:2591—8.
[93]KnollGA. Kidneytransplantation in theolder adult. AmJ KidneyDis2013;61:790—7.
[94]GillJ,SampaioM,GillJS,DongJ,Kuo H-T,DanovitchGM, etal.Inductionimmunosuppressivetherapyintheelderly kid-neytransplantrecipientintheUnitedStates.ClinJAmSoc Nephrol2011;6:1168—78.
[95]DurrbachA, Pestana JM,Pearson T, VincentiF,GarciaVD, CampistolJ,etal.AphaseIIIstudyofbelataceptversus cyclo-sporineinkidneytransplantsfromextendedcriteriadonors (BENEFIT-EXTstudy).AmJTransplant2010;10:547—57.
[96]DurrbachA, RostaingL, Tricot L, OualiN, WolfP, Pouteil-NobleC,etal.Prospectivecomparisonoftheuseofsirolimus andcyclosporineinrecipientsofakidneyfroman expanded-criteriadonor.Transplantation2008;85:486—90.
[97]Pallet N,Anglicheau D, Martinez F,Mamzer M-F, Legendre C, Thervet E. Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolatemofetilinrecipientsofakidneygraftfroman expanded-criteriadonor.Transplantation2006;81:949—52.
[98]Balupuri S,Buckley P,Snowden C,MustafaM, SenB, Grif-fiths P, et al. The trouble with kidneys derived from the non-heartbeatingdonor:asingle-center10-yearexperience.
Transplantation2000;69:842—6.
[99]González-SeguraC,Castelao AM,Torras J, MoresoF,Riera L, López-Costea MA, et al. A good alternative to reduce thekidneyshortage:kidneysfromnon-heartbeatingdonors.
Transplantation1998;65:1465—70.
[100]Balupuri S, Buckley P, MohamadM, ChidambaramV, Gers-tenkornC,SenB,etal.Earlyresultsofanon-heartbeating donor(NHBD)programmewithmachineperfusion.TransplInt 2000;13(Suppl.1):S255—8.
[101]Kokkinos C, Antcliffe D, Nanidis T, Darzi AW, Tekkis P, Papalois V. Outcome of kidney transplantation from non-heartbeating versus heartbeating cadaveric donors.
Transplantation2007;83:1193—9.
[102]Agencedelabiomédecine.Leplangreffe2012—2016. Saint-DenisLaPlaine:ABM;2012.
[103]Kootstra G, Daemen JH, Oomen AP. Categories of non-heartbeatingdonors.TransplantProc1995;27:2893—4.
[104]Sánchez-FructuosoAI,MarquesM,PratsD,ConesaJ,Calvo N,Pérez-ContínMJ,etal.Victimsofcardiacarrestoccurring outsidethehospital:asourceoftransplantablekidneys.Ann InternMed2006;145:157—64.
[105]GagandeepS,MatsuokaL,MateoR,ChoYW,GenykY,Sher L, et al.Expanding thedonorkidney pool: utilityof renal allograftsprocuredinasettingofuncontrolledcardiacdeath.
AmJTransplant2006;6:1682—8.
[106]LeGuen M,Nicolas-Robin A, CarreiraS, RauxM, Leprince P,Riou B, etal. Extracorporeallife support following out-of-hospital refractory cardiac arrest. Crit Care 2011;15:
R29.
[107]LamhautL,JouffroyR,SoldanM,PhillipeP,DeluzeT,JaffryM, etal.Safetyandfeasibilityofprehospitalextracorporeallife
supportimplementationbynon-surgeonsforout-of-hospital refractorycardiacarrest.Resuscitation2013;84:1525—9.
[108]Recommandationssurlesindicationsdel’assistance circula-toiredansletraitementdesarrêtscardiaquesréfractaires.
AnnFrAnesthReanim2009;28:182—6.
[109]Lee L. Human harvest. 2014 http://www.humanharvest-movie.com/.
[110]AntoineC,MoureyF.Conditionsàrespecterpourréaliserdes prélèvementsd’organessurdesdonneursdécédésaprèsarrêt circulatoiredelacatégorieIIIdeMaastrichtdansun établis-sementdesanté;2016http://www.agence-biomedecine.fr/
Arret-circulatoire-suite-a-un.
[111]PennI.Transmissionofcancerfromorgandonors.Ann Trans-plant1997;2:7—12.
[112]BuellJF,BeebeTM,TrofeJ,GrossTG,AllowayRR,Hanaway MJ,et al. Donor-transmitted malignancies.Ann Transplant 2004;9:53—6.
[113]GiessingM.Donorswithmalignancies-riskorchance? Trans-plantProc2012;44:1782—5.
[114]Feng S, Buell JF,Cherikh WS, Deng MC,Hanto DW, Kauff-manHM,etal.Organdonorswithpositiveviralserologyor malignancy:riskofdiseasetransmissionbytransplantation.
Transplantation2002;74:1657—63.
[115]KauffmanHM,McBrideMA,CherikhWS,SpainPC,MarksWH, RozaAM.Transplanttumorregistry:donorrelated malignan-cies.Transplantation2002;74:358—62.
[116]KauffmanHM,CherikhWS,McBrideMA,ChengY,HantoDW.
Deceased-donorswithapasthistoryofmalignancy:anorgan procurementandtransplantationnetwork/unitednetworkfor organsharingupdate.Transplantation2007;84:272—4.
[117]FengS,BuellJF,ChariRS,DiMaioJM,HantoDW.Tumorsand transplantation:the2003ThirdAnnualASTSState-of-the-Art WinterSymposium.AmJTransplant2003;3:1481—7.
[118]NalesnikMA,WoodleES,DimaioJM,VasudevB,TepermanLW, CovingtonS,etal.Donor-transmittedmalignanciesinorgan transplantation:assessmentofclinicalrisk.AmJTransplant 2011;11:1140—7.
[119]HassanainM.Novelguidelinesfororgandonorcancer scree-ning.AnnTransplant2014;19:241—7.
[120]ZhangS,YuanJ,LiW,YeQ.Organtransplantationfromdonors (cadavericorliving)withahistoryofmalignancy:reviewof theliterature.TransplantRev2014;28:169—75.
[121]Andrews PA, Burnapp L, Manas D, Bradley JA, Dudley C, British Transplantation Society, et al. Summary of the British TransplantationSociety/Renal AssociationUK guide-linesforlivingdonorkidneytransplantation.Transplantation 2012;93:666—73.
[122]Recommandationsformaliséesd’expertssurleprélèvement et lagreffeàpartir dedonneurvivant2014. http://www.
agence-biomedecine.fr/Recommandations-d-experts.
[123]Loh E, Couch FJ, Hendricksen C, Farid L, Kelly PF, Acker MA,etal.Developmentofdonor-derivedprostatecancerin arecipientfollowingorthotopichearttransplantation.JAMA 1997;277:133—7.
[124]YinM,BastackyS,ChandranU,BecichMJ,DhirR.Prevalence of incidental prostatecancer in thegeneral population:a studyofhealthyorgandonors.JUrol2008;179:892—5 [dis-cussion895].
[125]Schröder FH, HugossonJ, RoobolMJ,TammelaTLJ, Zappa M,NelenV,etal.Screeningandprostatecancermortality:
resultsoftheEuropeanRandomised StudyofScreeningfor Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027—35.
[126]AndrioleGL,CrawfordED,GrubbRL,BuysSS,ChiaD,Church TR,etal.Prostatecancerscreeningintherandomized Pros-tate,Lung,Colorectal,andOvarianCancerScreeningTrial:
mortalityresultsafter13yearsoffollow-up.JNatlCancer Inst2012;104:125—32.
[127]SalomonL,FeuilluB,PetitJ,SallustoF,LechevallierE, Esch-wegeP,etal.[EvaluationofserumPSAinbrain-deadsubjects overtheageof50beforeorganharvesting:organdonation and the riskof transmission of prostate cancer.Survey of thetransplantationcommitteeoftheAssociationfranc¸aise d’urologie].ProgUrol2007;17:828—31.
[128]DoerflerA,TillouX,LeGalS,DesmontsA,OrczykC, Bensa-dounH.Prostatecancerindeceasedorgandonors:areview.
TransplantRev2014;28:1—5.
[129]FiorentinoM,D’ErricoA,CortiB,CasanovaS,RidolfiL, Ven-turoliN,etal.Amultiorgandonorcancerscreeningprotocol:
theItalianEmilia-Romagnaregionexperience. Transplanta-tion2003;76:1695—9.
[130]D’Errico-GrigioniA,CortiB,FiorentinoM,PiriniMG,Ridolfi L,VenturoliN,etal.Ahistopathologicscreeningmethodfor rationaluseoforgansfromprostate-specificantigen-positive multiorgandonors:theItalianEmilia-RomagnaRegion expe-rience.Transplantation2004;78:941—4.
[131]FalconieriG,RoccoM,AngioneV,PizzolittoS.Intraoperative examinationfor suspectedprostaticcarcinoma:frozen sec-tionsin‘‘marginal’’(cadaveric)transplantdonors.PatholRes Pract2009;205:175—82.
[132]D’Errico-Grigioni A, Fiorentino M,Vasuri F,Corti B, Ridolfi L, GrigioniWF,et al. Expanding thecriteriaoforgan
[132]D’Errico-Grigioni A, Fiorentino M,Vasuri F,Corti B, Ridolfi L, GrigioniWF,et al. Expanding thecriteriaoforgan